Cell Therapy Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The cell therapy market is expected to witness a CAGR of 6.8% over the forecast period.
The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most of the companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to show a positive impact on the studied market as most of the pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, in November 2020, Novartis obtained the license for the Mesoblast’s cell therapy remestemcel-L for the treatment of COVID-19. Thus, owing to the growing research activities pertaining to the development of cell therapies in treating SARS-CoV2 infection, the studied market is expected to be impacted during the COVID-19 pandemic era.
The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
Chronic diseases and conditions are on the rise worldwide. According to the Global Alliance for Chronic Diseases (GACD) 2018, 1 in 10 individuals was predicted to have type 2 diabetes by 2035 worldwide, and diabetes is predicted to be the 7th leading cause of death by 2030. According to Globocan 2020, the new cancer cases diagnosed accounted for 19,292,789 in 2020 worldwide, with 9,958,133 deaths due to cancers globally. Among all cancers, breast cancer accounted for 2,261, 419 new cancer cases, followed by lung (2,206,771), prostate (1,414,259), and colon (1,148,515) in 2020. Additionally, as per the International Diabetes Federation Diabetes Altas Ninth Edition 2019, nearly 463 million population globally were living with diabetes worldwide, and the number is expected to reach 700 million by 2045.
Therefore, the increasing prevalence of chronic conditions, government assistance, and numerous companies investing heavily in stem cell therapy research and development are predicted to help to stimulate industry growth. The proven effectiveness of cell therapy products, coupled with the increasingly favorable guidelines on cell therapy research and manufacturing, is likely to positively impact the studied market over the forecast period.
Scope of the Report
As per the scope of the report, cell therapy is known as a type of therapy in which live cells are injected into a patient for the treatment of a number of disorders. This is a technology, which relies on replacing diseased or dysfunctional cells with healthy functioning ones. Cells mainly used for such advanced therapies are stem cells because of their ability to differentiate into the specific cells required for repairing damaged or defective tissues or cells. Moreover, cell therapy finds its application in the development of regenerative medicines.
The cell therapy market is segmented by Type, Therapy, Application, and Geography. By Type, the market is segmented into Autologous and Allogeneic. By Therapy, the market is segmented into Mesenchymal Stem Cell Therapy, Fibroblast Cell Therapy, Hematopoietic Stem Cell Therapy, and Other Therapies. By Application, the market is segmented into Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, and Other Applications. By Geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The report offers the value (in USD million) for the above segments.
|Mesenchymal Stem Cell Therapy|
|Fibroblast Cell Therapy|
|Hematopoietic Stem Cell Therapy|
|Dermatology and Wounds|
Key Market Trends
The Allogeneic Therapies Segment is Expected to Account for the Largest Share in the Cell Therapy Market
Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.
Moreover, cancer recurrence is one of the foremost concerns of patients and their caregivers. Fear of recurrence can negatively affect the quality of life, and as per the “cancer recurrence statistics” published in 2018, approximately 7% of patients develop severe and disabling fear that includes constant intrusive thoughts and misinterpretation of mild and unrelated symptoms. These recurrences are usually observed in children and patients suffering from breast and oropharyngeal cancer. Allogenic transplantation is recommended for patients with a high risk of relapse after successive courses of induction chemotherapy. Thus, an increase in the incidence of cancer relapse has provided growth avenues to the demand for allogeneic therapies. Furthermore, the rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities to the segmental growth.
Thus, owing to the rising number of research on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Market Over the Forecast Period
North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that supports the research activities in the United States. Factors attributing to the high growth of the studied market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
There is a tremendous amount of funding in the United States available to increase R&D activities in the field of cancer. As per the data published by the National Cancer Institute (NCI), in 2019, the Department of Defense and Labor, the Department of Health and Human Services, and the Education Appropriations Act allotted USD 5.74 billion to the NCI, which indicated a USD 79 million increase over FY 2018. As cell therapies have huge potential in treating cancer, the availability of funding is expected to further help in overall market growth. In July 2020, the US FDA approved Tecartus (brexucabtagene autoleucel), cell-based gene therapy for the treatment of mantle cell lymphoma (MCL). In July 2020, FDA also approved Talaris Therapeutics Inc., an investigational new drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis (SSC). Moreover, as per the Regulatory Affairs Professionals Society, in 2019, the US FDA granted 34 designations associated with regenerative medicine advanced therapy, wherein 68 out of 100 were cell therapy products. Thus, the rising adoption of regenerative medicines and related clinical studies in the region is anticipated to propel market growth over the forecast period.
To understand geography trends, Download Sample Report
The cell therapy market is moderately competitive, with the presence of a considerable number of companies. The major companies of the studied market are Pharmicell Co. Ltd, Corestem Inc., Chiesi Farmaceutici SpA, Tegoscience, Anterogen Co. Ltd, TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt Ltd, Nipro Corporation, and Medipost Co. Ltd. These companies are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaborations to secure the market position. For instance, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. announced a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat in Multiple Myeloma patients.
- In August 2020, Novartis AG received US FDA's approval for its Kesimpta, targeted B-Cell therapy for relapsing multiple sclerosis.
- In April 2020, Gilead Sciences Inc., Kite, a Gilead Company, and oNKO-Innate entered into a collaboration to support research, discovery, and development of next-generation cell therapies based on Natural Killer (NK) cells.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Conditions
4.2.2 Rising Adoption of Regenerative Medicine
4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
4.3 Market Restraints
4.3.1 High Cost of Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
5.2 By Therapy
5.2.1 Mesenchymal Stem Cell Therapy
5.2.2 Fibroblast Cell Therapy
5.2.3 Hematopoietic Stem Cell Therapy
5.2.4 Other Therapies
5.3 By Application
5.3.4 Dermatology and Wounds
5.3.5 Other Applications
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Anterogen Co. Ltd
6.1.2 Tego Science
6.1.3 Chiesi Farmaceutici SpA
6.1.4 Corestem Inc.
6.1.5 Pharmicell Co. Ltd
6.1.6 Fibrocell Technologies Inc.
6.1.7 Nipro Corporation
6.1.8 MEDIPOST Co. Ltd
6.1.9 TiGenix (Takeda Pharmaceuticals)
6.1.10 Stempeutics Research Pvt Ltd
6.1.11 Gilead Sciences Inc. (Kite Pharma Inc.)
6.1.12 Allogene Therapeutics Inc.
6.1.13 Novartis AG
6.1.14 Vericel Corporation
6.1.15 Organogenesis Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Cell Therapy Market market is studied from 2018 - 2026.
What is the growth rate of Global Cell Therapy Market?
The Global Cell Therapy Market is growing at a CAGR of 6.8% over the next 5 years.
Which region has highest growth rate in Global Cell Therapy Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Cell Therapy Market?
North America holds highest share in 2020.
Who are the key players in Global Cell Therapy Market?
PHARMICELL Co., Ltd , Corestem Inc., Chiesi Farmaceutici S.p.A., Tego Science, Anterogen Co., Ltd. are the major companies operating in Global Cell Therapy Market.